Viking Therapeutics

News

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

News

Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.